US-based medical technology firm Becton Dickinson (BD) has completed a $12.2bn acquisition of biomedical equipment maker CareFusion.

First announced in October 2014, the acquisition received approval from the European Commission under EU Merger Regulation.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

As part of the transaction, BD paid $58 per share in cash and stock to shareholders of the US-based biomedical equipment maker.

Under the deal, CareFusion shareholders received $49 in cash and 0.0777 of a share of BD for each share of CareFusion, and the company is allowed to become a wholly-owned subsidiary of BD.

BD shareholders currently own 92% of the combined company and CareFusion shareholders will own the remaining 8%.

"BD shareholders currently own 92% of the combined company and CareFusion shareholders will own the remaining 8%."

BD president Vincent Forlenza said: "We are very excited to announce the consummation of the CareFusion acquisition, as it represents a major milestone in BD’s 118-year history.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

"We look forward to the future with confidence as we become one of the largest global leaders in medical technology, and are better positioned to partner with healthcare providers around the world to provide safer, more economical and improved care."

As a result of the acquisition, CareFusion is now a wholly-owned subsidiary of BD, while its shares stopped trading, and will be delisted from New York Stock Exchange (NYSE).

In the second half of fiscal year 2015, CareFusion will be included in a new BD Medical segment structure.

CareFusion develops Alaris infusion pumps and IV sets, MaxPlus and MaxZero IV connectors and sets, Pyxis automated dispensing and patient identification systems.

The company also produces AVEA, LTV series, AirLife ventilator and respiratory products, ChloraPrep products, MedMined services for data mining surveillance, V Mueller surgical instruments, as well as products that support interventional medicine.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact